Serine-arginine protein kinase 1 is associated with breast cancer progression and poor patient survival
Serine-arginine protein kinase 1 is associated with breast cancer progression and poor patient survival
复制标题
丝氨酸-精氨酸蛋白激酶 1 与乳腺癌进展和患者生存率低相关
DOI：
10.1007/s12032-014-0083-8
复制
发表时间：
2014-08-01
期刊：
影响因子：
3.4
通讯作者：
Lin, Xi
中科院分区：
文献类型：
--
作者：
Li, Xing-hua;Song, Jun-wei;Lin, Xi
乳腺癌是最常见的癌症，也是全世界妇女死亡的第二大原因。有必要鉴定有价值的分子标志物来预测乳腺癌患者的进展和治疗效果。丝氨酸精氨酸蛋白激酶1 （SRPK1）是SR激酶家族的一员，可磷酸化SR剪接因子，在正常细胞发育和多种人类疾病中发挥重要作用。在目前的研究中，我们想探讨SRPK1在乳腺癌中的表达与其临床特征之间是否存在关系。结果表明，通过定量逆转录酶PCR和Western blotting检测，SRPK1在乳腺癌细胞系和组织中mRNA和蛋白水平均上调。免疫组化分析显示，SRPK1在132例乳腺癌患者石蜡样品中高表达；统计学分析表明，SRPK1高表达与乳腺癌患者临床分期（P < 0.001）、TNM分型（P < 0.05）显著相关。SRPK1低表达可延长患者生存时间，而SRPK1高表达可缩短患者生存时间。多因素分析显示，SRPK1的上调可能是乳腺癌患者预后的独立预后指标。综上所述，SRPK1的上调可能在乳腺癌的进展中发挥重要作用，可能被认为是这种恶性肿瘤的潜在诊断和治疗靶点。
Breast cancer is the most common cancer and the second leading cause of mortality for women worldwide. It is necessary to identify valuable molecular markers to predict breast cancer progression in patients and treatment effect. Serine-arginine protein kinase 1 (SRPK1), a member of SR kinase family, phosphorylates the SR splicing factors which plays essential roles in normal cell development and multiple human diseases. In the current study, we wanted to explore if there are any relationships between SRPK1 expression in breast cancer and its clinical characteristics. The results showed that SRPK1 is upregulated in breast cancer cell lines and tissues at both mRNA and protein levels, measured by quantitative reverse transcriptase PCR and Western blotting. Immunohistochemical analysis showed a high expression of SRPK1 in 132 paraffin samples of patients with breast cancer; statistical analyses demonstrated that high expression of SRPK1 significantly correlated with clinical staging of patients with breast cancer (P < 0.001), TNM classification (P < 0.05). Low expression of SRPK1 leads to longer survival time, while high expression of SRPK1 leads to shorter survival time of patients. Multivariate analysis revealed that upregulation of SRPK1 might be an independent prognostic marker for the outcomes of patients with breast cancer. In conclusion, upregulation of SRPK1 might play an important role in the progression of breast cancer and might be considered as the potential diagnostic and therapeutic target to this malignancy.